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ABSTRACT 
 
In this study, pH-responsive amphiphilic chitosan (CS) nanoparticles were used to encapsulate 
quercetin (QCT) for sustained release in cancer therapy. The novel CS derivatives were 
obtained by synthesis with 2,3-epoxy-1-propanol, also known as glycidol, followed by 
acylation with dodecyl aldehyde. Characterization was performed by spectroscopic, 
viscosimetric, and size-determination methods. Critical aggregation concentration, 
morphology, entrapment efficiency, drug release profile, cytotoxicity, and hemocompatibility 
studies were also carried out. The average size distribution of the self-assembling 
nanoparticles measured by dynamic light scattering ranged from 140 to 300 nm. In vitro QCT 
release and Korsmeyer–Peppas model indicated that pH had a major role in drug release. 
Cytotoxicity assessments indicated that the nanoparticles were non-cytotoxic. 3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay further revealed that QCT-
loaded nanoparticles could inhibit MCF-7 cell growth. In vitro erythrocyte-induced hemolysis 
indicated the good hemocompatibility of the nanoparticles. These results suggest that the 
synthesized copolymers might be potential carriers for hydrophobic drugs in cancer therapy. 
© 2017 Wiley Periodicals, Inc. J. Appl. Polym. Sci. 2018, 135, 45678. 
INTRODUCTION 
Chitosan (CS) is a natural polymer that can be extracted from exoskeletons of insects and 
crustaceans. Due to its low toxicity, biodegradability, and biocompatibility,1-3 many 
biological applications have been reported for CS, including tissue engineering for cell 
cultures,4-6 wound healing,7, 8 gene9-11 and drug delivery,12, 13 antibacterial14, 15 and 
antifungal activities.16-19 Due to its ability to self-assemble in solution forming nanoparticles, 
amphiphilic derivatives of CS are widely used in many biological applications, such as carriers 
for genes, proteins, and drugs.20, 21 Normally, amphiphilic derivatives are obtained by the 
addition of hydrophilic and hydrophobic groups to the polymer backbone. This modification 
increases the intra- and intermolecular interactions responsible for the aggregation process. 
Nanotechnology has emerged as a potential tool in cancer therapy. Advances in materials 
science and cancer biology have contributed to improved therapeutic systems. Nanoscale 
carriers can selectively release drugs into the tumor regions by exploring specific 
characteristics of the cancerous tissues, reducing side effects on healthy cells. These 
characteristics include leaky vasculature, angiogenesis, presence of specific enzymes, pH 
changes, among others.22-24 pH-sensitivity polymers, such as CS, can be used as carriers for 
cancer therapy, since fermentative glycolysis in cancer tissues might lead to acidic conditions 
in the extracellular region decreasing the local pH to values as low as 5.0.25-27 After reaching 
these regions, the carrier systems may release the drug by responding to pH changes in the 
extracellular fluids of the tumor tissues. 
The CS backbone can be protonated/deprotonated according to the pH of the medium being 
below or above its pKa (≈6.4), respectively.28 This characteristic gives this polymer pH 
sensitivity, since the properties and structure of CS change according to its protonation. 
Therefore, it is possible to use amphiphilic derivatives as pH-sensitive drug carriers in cancer 
therapy. Although studies involving amphiphilic CS have been undertaken to produce 
derivatives with improved self-assembling characteristics, biological properties of these 
systems need to be optimized. In cancer treatment, carriers should have low cytotoxicity, 
good hemocompatibility, and adequate specificity for tumor regions. 
Epoxide derivatives are widely used reagents due to their very reactive groups.29 The 
structure of this cyclic ether is an equilateral triangle with bond angles of 60° and slight 
differences in electronegativity are due to the carbon–oxygen bonds. This makes these 
compounds powerful electrophiles that can react with nucleophiles, such as the amine groups 
present in the CS backbone. The small 2,3-epoxy-1-propanol molecule, also known as glycidol 
(GLY), containing epoxide and hydroxyl functional groups was used as a hydrophilic grafting 
agent to modify CS. 
In this research, a novel amphiphilic co-polymer was synthesized by grafting GLY to the CS 
backbone, followed by reductive alkylation with different amounts of dodecyl aldehyde (DDA) 
(Figure 1). The derivatives were characterized by 1H nuclear magnetic resonance (NMR), 
attenuated total reflectance-Fourier transform infrared spectroscopy (ATR-FTIR), and 
ultraviolet–visible (UV–vis) spectroscopy. The behavior of the self-assembled amphiphilic 
derivatives in aqueous solution was determined by fluorescence spectroscopy. Dynamic light 
scattering (DLS) was used to monitor average size and ζ-potential of the particles. The release 
of quercetin (QCT) from the nanoparticles was investigated at different pHs. Cytotoxicity 




Schematic representation of the synthesis of the amphiphilic derivatives of CS. 
EXPERIMENTAL 
Materials 
CS powder [low-molecular weight, deacetylation degree (DD) ≥ 85%], GLY, DDA, sodium 
hydroxide, sodium acetate, acetic acid, and pyrene were reagent grade and used as received 
from Sigma Aldrich Chemical Co., Brazil. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) and RPMI-1640 cell culture medium were purchased from Sigma-Aldrich 
GmbH, Germany. Ultrapure MilliQ water was used throughout. 
Deacetylation of CS 
Deacetylated CS (D-CS) was prepared in aqueous NaOH solution as described 
earlier.30 Briefly, commercial CS powder (C-CS) (12.0 g, 7.44 × 10−2 mol of monosaccharide 
units) was dissolved in aqueous acetic acid (400 mL, 2 wt %) for 12 h to ensure the complete 
solubilization. Subsequently, this solution was added drop-wise to aqueous NaOH (200 mL, 
50 wt %) at room temperature. The suspension was allowed to react in nitrogen atmosphere 
at 105 °C for 1.5 h. After the reaction time, the suspension was filled with preheated water at 
60 °C up to 4 L. Subsequently, the precipitate was washed five times with water, separated 
by filtration, and the procedure was repeated to achieve a higher DD. The polymer was 
isolated by lyophilization after purification by dialysis against water for 5 days (yield 11.1 g, 
92.5%). The DD of the N-D-CS was calculated using the integrals of the peaks of the 1H-NMR 
spectra corresponding to the protons of the N-acetyl group at 2.3 ppm and the peak due to 
the C2 proton at 5.3 ppm.31 
Depolymerization of CS 
The depolymerization of CS was carried out by oxidation with sodium nitrate in acid solution 
using the procedure described by Tommeraas et al.32 Approximately, 10.0 g of previously D-
CS were solubilized in 555 mL of acetic acid solution (2 wt %) for 12 h. Then the solution was 
purged with nitrogen for 1 h under constant stirring and cooled at 4 °C. Afterward, the stirring 
was stopped and 18.6 mL of aqueous sodium nitrite (231 mg) was added to the mixture and 
the reaction was kept at 4 °C for 18 h in the absence of light. After this reaction time, the 
resulting solution was precipitated with sodium hydroxide and centrifuged at 10,000 rpm. The 
precipitate was then washed with deionized water and the obtained product was lyophilized. 
Syntheses 
GLY-Modified CS 
Hydrophilic CS grafted with GLY was prepared by dispersing 6.0 g (3.72 × 10−2 mol) of CS in 
aqueous acetic acid (300 mL, 2 wt %). After complete solubilization, 9.5 mL of GLY were added 
drop-wise to the solution and the mixture was refluxed at 50 °C for 24 h. The polymer was 
purified by dialysis against water, isolated by lyophilization and characterized by 1H-NMR and 
ATR-FTIR. 
Preparation of Amphiphilic CS 
Amphiphilic derivatives were obtained by the previously described method.33 Briefly, GLY-
modified CS (3.0 g, 1.2 × 10−2 mol), dissolved in acetic acid (0.2 M, 330 mL), was added drop-
wise to ethanol (240 mL). Afterwards, different amounts of DDA dissolved in ethanol (10 mL) 
were added and the mixture was stirred for 1 h at room temperature. Sodium 
cyanoborohydride was added and the solution was allowed to react for 24 h under stirring at 
room temperature. The final product was purified by dialysis against water for 3 days, isolated 
by lyophilization and characterized by 1H-NMR and ATR-FTIR. 
Characterization Methods 
Viscosity 
Molar masses were determined from intrinsic viscosities measured using a digital rolling-ball 
viscometer (Lovis 2000 MME, Anton Paar, Graz, Austria). Measurements were made at 
concentrations in the 3.0–7.0 × 10−3 g/mL range at pH 4.5 using an acetic acid (0.3 M)/sodium 
acetate (0.2 M) buffer. The average viscosimetric molecular weights of C-CS, D-CS, and 
depolymerized low-molecular-weight CS (L-CS) were determined from the intrinsic viscosities, 
η, using the Mark–Houwink equation and the constants, a = 0.76 and K = 0.076 mL/g for C-CS 
and, a = 0.82 and K = 0.076 mL/g for D-CS and L-CS, as suggested by Rinaudo et al.34 
1H-NMR Spectroscopy 
Samples were prepared by dissolution of ∼10 mg of CS samples in 1 mL of deuterium oxide 
(D2O) and 10 μL of deuterium chloride. After complete solubilization, the 1H-NMR spectra 
were recorded on an Agilent 400/54 Premium Shielded spectrometer at 70 °C. 
ATR-FTIR Analysis 
ATR-FTIR analysis (Perkin Elmer Frontier FTIR spectrometer, Perkin Elmer, Shelton, CT) was 
performed on freeze-dried samples to confirm the occurrence of the reaction between CS 
and GLY and DDA. All spectra were recorded at room temperature and four scans were 
averaged over the of 4000–600 cm−1 range. 
Derivatives Solubility 
The transmittance of the derivatives samples at 550 nm (wavelength at which CS does not 
absorb) was used to monitor the solubility as function of the pH. Approximately, 20 mg of the 
samples were dissolved in 20 mL of acetic acid (0.10 M).31 After complete solubilization, 
portions of NaOH (25 µL, 0.5 M) were added to the solution up to pH 12. The pH was 
measured with a UB-10 pH-meter (Denver Instrument, Bohemia, NY) and the transmittance 
was recorded on a UV-2550 ultraviolet–visible spectrophotometer (Shimadzu, Kyoto, Japan). 
Critical Aggregation Concentrations 
Fluorescence measurements were recorded on a Hitachi F4500 spectrophotometer using 
pyrene as a hydrophobic fluorescence probe to measure the self-aggregation behavior of the 
derivatives.2 Pyrene, dissolved in methanol (1 × 10−3 M) was added to solutions of the 
derivatives (1.0 g/L) in order to obtain 5.0 × 10−6 M solutions of the probe. The I1/I3 ratio 
between the first (373 nm) and the third (382 nm) vibronic peaks of the probe fluorescence 
was used to evaluate the local environment polarity of the nanoparticles. Pyrene was excited 
at 310 nm and its emission spectra were recorded from 350 to 500 nm. 
Particle Size Distribution and Zeta Potential 
The size distribution of the particles were determined using DLS with non-invasive back 
scattering (DLS-NIBS) at an angle of 90°. The zeta (ζ)-potential was measured by mixed laser 
Doppler velocimetry and phase analysis light scattering (M3-PALS). A Malvern Zetasizer 
NanoZS (Malvern Instruments Ltd., Worcestershire, UK) fitted with a red laser (λ = 632.8 nm) 
at 25 °C was used to conduct both determinations. Derivative solutions were prepared at 
concentration 0.1–1.0 g/L, at pH 5.0 (acetate buffer) and 7.4 (phosphate buffer). 
Transmission Electron Microscopy Observation 
A JEM2100 LaB6 (Jeol, Japan) transmission electron microscope operating at 200 keV was 
used to assess the surface morphology of the nanoparticles. The sample solution (0.5 mg/mL, 
20 µL) was placed onto the carbon-coated 200 mesh copper grid and air-dried for 20 min. 
Afterwards, the grids were stained with phosphotungstic acid at 2% and dried at room 
temperature before transmission electron microscopy (TEM) observations. 
Evaluation of QCT Loading and Release 
QCT-loaded nanoparticles were prepared using a centrifugation method. Briefly, 20 mg of 
sample were dispersed in 3 mL of sodium acetate buffer (pH 5.0). After gentle stirring for 8 h, 
ethanolic QCT solutions were added and the mixture was allowed to stir for another 4 h in 
the dark. Centrifugation (15,000 rpm for 50 min at 15 °C) was used to isolate the QCT-loaded 
nanoparticles. The free QCT concentration in the supernatant was determined by UV–visible 
spectrophotometry. The entrapment efficiency (EE) and the drug loading (DL) efficiency were  
calculated using 
 




Sodium acetate buffer (pH 5.0) and phosphate buffer saline (PBS, pH 7.4) were used as media 
for the QCT release studies. The centrifuged nanoparticles were re-suspended in the desired 
buffer solution and transferred to a Pur-A-Lyzer Mini Dialysis Kit (MWCO 6–8 kDa). The dialysis 
tubes were immersed in 35 mL of the corresponding buffer solution, under gentle stirring at 
37 ± 0.5 °C. At the sampling times, 3 mL of the release media were collected for evaluation of 
the amount of released QCT using UV–visible spectrophotometry.35 An equal volume of fresh 
buffer was replaced in the solution after each withdrawal. 
The drug release mechanism from nanoparticles was evaluated using the Korsmeyer–Peppas 
model [eq. 3]36, 37  
 
  (3) 
 
where Mt is the mass of QCT released at time t, M∞ is the total mass of QCT to be released, 
and k is a constant dependent on the structural characteristics of the nanoparticles, solvent, 
and material interactions. The diffusion, represented by the exponent n, is considered Fickian 
when n = 0.43 and case II transport when n = 0.85. Anomalous diffusion takes place when n is 
between these values. When n > 0.85 the diffusion involves super-case II transport. Fickian 
diffusion can also happen when n is lower than 0.43, if the system is polydispersed with 
spherical particles.38 The model was applied for release up to Mt/M∞ < 0.6. 
Cytotoxicity Assay 
The effects of the free QCT, blank, and loaded nanoparticles on the viability of human breast 
cancer cells (MCF-7) were evaluated using the MTT assay. Cells were seeded in the 96-well 
plate at a density of ∼104 cells per well (or ∼105 cells/mL) and cultured for 24 h (RPMI 1640 
medium (Sigma-Aldrich) supplemented with 10% (vol/vol) fetal bovine serum, 1% (vol/vol) l-
glutamine (200 mM) and 1% (vol/vol) penicillin–streptomycin (10,000 units penicillin, 10,000 
units of streptomycin in 0.9% NaCl). Each well was washed with supplement-free medium 
before adding the sample. After an additional incubation with different concentrations of the 
samples, the wells were washed twice with supplement-free medium. Immediately, 100 μL 
of the medium and 25 μL of MTT solution in PBS (5 mg/mL) were added to each well. After 
further incubation for 4 h, the dye was solubilized with 150 μL of dimethylsulphoxide (DMSO) 
using orbital shaking at 300 rpm for 15 min. A microplate reader (Safire, Tecan AG, Salzburg, 
Austria) was used to measure the absorbance at 570 nm. Relative viability (%) values were 
calculated according to the absorbance ratio of the wells treated with samples and wells 
containing untreated cells (negative control). 4% Triton X-100 in PBS solutions was used as 
positive control. All experiments were carried out as independent triplicates on different days 
to determine averages and standard deviations. 
Blood Compatibility Assessments 
The hemocompatibility tests were performed by diluting 800 µL of freshly collected pig blood 
with 1 mL of PBS buffer. Approximately 20 µL of diluted blood were added to1 mL of 
nanoparticles dispersed in PBS (1 mg/mL) and incubated for 60 min at 37 °C. Afterward, the 
hemolysis ratio (HR) was calculated using the absorbance of the samples at 545 nm in the 
following equation 
 
                  (4) 
 
where Asample, APBS, and Awater are the absorbance at 545 nm of blood samples treated with 
nanoparticles, PBS (negative control), and water (positive control), respectively. All the 
hemocompatibility experiments were done in triplicate. 
 
 
RESULTS AND DISCUSSION 
Characterization of the Amphiphilic Derivatives 
Regardless of its advantages, the poor solubility of CS in water has been a crucial barrier to its 
modification and applications. To improve its solubility, a novel water-soluble GLY-grafted CS 
was synthesized. In addition, this hydrophilic CS was further modified with the hydrophobic 
group DDA in order to improve the amphiphilic character of the samples, which can self-
assemble in aqueous solution. It is also known that the molecular weight of the CS is an 
essential factor affecting the self-assembling process, since long CS chains can obstruct the 
movement of the backbone during the procedure.28 Therefore, to optimize the assembling 
properties, the D-CS was depolymerized before further modifications. The molecular weight 
for C-CS, D-CS, and deacetylated with L-CS are shown in Table 1. 
Table 1. Amphiphilic Derivatives Characterization and Viscosity-Average Molecular Weight 
 
Sample DDa (%) DS1b (%) DS2c (%) Mv (kDa) 
C-CS 84.3 — — 82.4 
D-CS 97.1 — — 50.4 
L-CS 97.1 — — 3.8 
L-CS-GLY40 — 38.7 — — 
L-CS-GLY40D7 — 38.7 7.5 — 
L-CS-GLY40D34 — 38.7 34.3 — 
 
a Deacetylation degree. 
b Degree of substitution at the hydrophilic chain. 
c Degree of substitution at the hydrophobic chain. 
 
As shown in Figure 1, GLY-grafted CS was obtained by nucleophilic substitution of the C-2 
amine groups with GLY. The final product was characterized by 1H-NMR and FTIR to confirm 
the presence of the chemical bonds of the substituents. L-CS sample was used as starting 
material. 
 
1H-NMR spectra [Figure 2(a,b)] were used to calculate the DD of the derivatives. The areas 
corresponding to acetamido methyl protons (δ = 2.35 ppm) and the doublet corresponding to 
the resonance of the anomeric proton at δ = 5.21 ppm were used in eq. 5.39 The DD, 
expressed in —NH2 mol %, was 84.3% for C-CS and 97.1% for D-CS and L-CS. 
 
 





 Figure 2 
 1H-NMR spectra of (a) C-CS, (b) deacetylated L-CS, (c) the hydrophilic derivative 
 containing 38.7% of GLY (L-CS-GLY40), and its amphiphilic derivatives containing (d) 
 38.7% of hydrophilic groups and 7.5% of the hydrophobic chain (L-CS-GLY40D7) and (e) 
 38.7% of hydrophilic groups and 34.3% of the hydrophobic chain (L-CS-GLY40D34). 
 
The degree of substitution by the reaction with GLY (DS1) was calculated from the 1H-NMR 
spectra of the CS derivative [Figure 2 (c)]. The broad peaks at δ = 2.97 ppm and δ = 3.26 ppm 
can be attributed to protons bonded to the carbons of the —CH2OH group in the N-(2,3-
dihydroxypropyl) moieties (—CH2CHOHCH2OH). The DS1 was estimated based on the 
comparison of the peak areas at δ = 2.97 ppm with that of the anomeric protons at δ = 4.91 
ppm and δ = 5.10 ppm. Using eq. 6 the degree of substitution DS1 of L-CS-GLY40 could be 
calculated as being 38.7%. 
 
  (6) 
 
The degree of substitution (DS2) by the hydrophobic dodecyl group (DDA) was calculated 
using eq. 7 and the areas at δ = 1.21 ppm attributed to resonance of the protons of the methyl 
group present in the C12 chain of the DDA substituent, and the anomeric protons at δ = 4.94 
ppm and δ = 5.11.30 The signals in the region 1.54 to 1.77 ppm are due to the resonance of 
methylene hydrogen in the C12 moieties [Figure 2(d,e)]. 
 
   (7) 
 
The DS2 for L-CS-GLY40D7 was 7.5% and for L-CS-GLY40D34 was 34.3%. Table 1 shows the DS at 
different sites of the compounds. 
FTIR spectra for deacetylated L-CS, GLY-grafted CS derivative (L-CS-GLY40), and the amphiphilic 




FTIR spectra of (a) deacetylated L-CS, (b) GLY-grafted CS (L-CS-GLY40), and its 
amphiphilic derivatives (c) L-CS-GLY40D7 and (d) L-CS-GLY40D34. 
 
The decrease of the peak intensity around 1595 cm−1, related to the N H bending vibration 
of the primary amino group, when comparing the FTIR spectra of D-CS [Figure 3(a)] with the 
derivatives [Figure 3(b–d)], is an evidence that hydrophilic GLY molecule reacted with the 
primary amine (—NH2) of the CS chain.40 It is also possible to see that all samples have a 
characteristic band around 3400 cm−1 due to the axial stretching vibration of the hydroxyl 
groups (O—H) of CS chains and residual free water.41 
 
Characteristic peaks can be seen at 2923 and 2850 cm−1 for the amphiphilic samples, 
corresponding to the axial deformation of the carbon–hydrogen bond of the CH3 and 
CH2 groups, respectively, present in the C12 chain of the dodecyl substituent. The FTIR spectra 
also show that when increasing the substitution of DDA on CS, the peaks at 2923 and 2850 
cm−1 become sharper, which indicates indirectly the increase of the substitution by DDA. The 
peak at 2333 cm−1 that can be seen in the L-CS-GLY40D7 and L-CS-GLY40D34 spectra is related 
to the vibration of the DDA-substituted amino groups.42 
 
Behavior in Aqueous Solution 
 
The derivatives modified with hydrophilic (GLY) and hydrophobic (DDA) substituents self-
assemble in aqueous solution due to their amphiphilic character. Nonetheless, the high-
molecular weight of CS could obstruct the movement of the backbone during the self-
assembling process. Therefore, low-molecular-weight L-CS-GLY was selected as the starting 
material to optimize the assembling properties. 
 
The solubility of L-CS and the amphiphilic compounds were evaluated by monitoring the 
changes in the transmittance of the solutions as function of pH. It is possible to observe in 
Figure 4 that the presence of hydrophilic groups in the modified CS increases the solubility of 
the polymer over the entire range of pH. On the other hand, for the starting unmodified CS L-
CS (pKa ≈ 6.4) the transmittance at 550 nm decreases sharply at pH higher than 6.2, for the L-
CS-GLY40 sample this transmittance was kept at about 99% over the whole pH range, up to 
12. The amphiphilic L-CS-GLY40D7 does not change its transmittance when increasing the pH. 
On the other hand, for the more substituted amphiphilic derivative L-CS-GLY40D34 the 
transmittance decreased from 88% to 79% when changing from acid to basic media. However, 
it is much more soluble than the unmodified CS at higher pH. The increase of the hydrophobic 
substitution (L-CS-GLY40D7 vs. L-CS-GLY40D34) results in a lower transmittance, probably due 




Transmittance versus pH of the derivatives solutions at 550 nm. 
 
The higher solubility of the GLY modified derivatives is due to the presence of two hydroxyl 
groups in the small glycidyl chain. The formation of hydroxyl–water hydrogen bonds 
compensates the nonpolar repulsion of the rest of the polymer chain, providing excellent 
solubility to CS. Although we are using this water-soluble CS to form amphiphilic polymer, it 
is possible to explore the use of this hydrophilic derivative in other areas such as delivery of 
DNA and siRNA,43 thermosensitive hydrogel,44 and oral enhancer,45 which corroborates the 
importance of synthesis described here. 
 
As already shown in a previous work, 30 pyrene can be used as fluorescence probe to track 
the aggregation behavior of these samples in aqueous solution. This probe does not affect 
the structure of the aggregates and the I1/I3 ratio of the intensity of the fluorescence peaks 
of pyrene can be correlated with the polarity of the media, which can be used to determine 
the critical aggregation concentrations (CAC).46 I1/I3 ratios in the 2.0–1.3 range indicate that 
the probe is placed in hydrophilic environments, whereas values below 1.2 indicate a 
hydrophobic medium. 
 
The CAC values were determined monitoring the variation of the I1/I3 ratio of the pyrene 
peaks intensity with increasing CS concentrations (Supporting Information Figure S1). The pH 
dependence of the CAC for both amphiphilic derivatives are listed in Table 2. It can be seen 
that aggregation starts at concentrations in the range 0.003–0.047 g/L and the CAC decreases 
slightly with the increasing degree of substitution by DDA. That can be explained by the fact 
that the hydrophobicity increases with higher degree of substitution by the C12 chain, which 
allows stronger self-aggregation in water solution due to the formation of more compact 
hydrophobic cores. 
Table 2. CAC of the Amphiphilic Derivatives at Different pH 
 
 
CAC (g/L × 10−3) 
Sample pH 4.0 pH 5.0 pH 6.2 pH 7.4 
L-CS-GLY40D7 47.3 21.6 15.1 4.5 
L-CS-GLY40D34 36.0 18.1 12.0 3.1 
 
The change with pH can be ascribed to the protonation/deprotonation of the remaining free 
amino groups of CS that change the electrostatic interaction among the chains, resulting in 
particles with different properties and CAC.47, 48 No sign of aggregation was observed for 
the hydrophilic derivative (L-CS-GLY40) even at higher concentrations. This behavior is in 
agreement with those obtained by solubility measurements (Figure 4). 
 
DLS-NIBS was used to measure the average size of the particles at pH 5.0 and 7.4 (acetate and 
phosphate buffers, respectively) and the results are shown in Table 3 and Figure 5. The size 
of the nanoparticles was in the range of 130–300 nm and is similar to those reported in the 




Average size of the particles versus polymer concentrations at pH 5.0 and 7.4. 
Table 3. Size and ζ-Potential of the Derivatives at Different pH 
 
 
Sample Concentration (g/L) Size (d.nm) Zeta 
pH 5.0 L-CS-GLY40D7 0.10 231 ± 2 14.1 ± 1.5 
  
0.25 234 ± 27 15.6 ± 0.7 
  
0.50 279 ± 13 17.8 ± 0.6 
  
1.00 294 ± 23 14.5 ± 0.6 
 
L-CS-GLY40D34 0.10 148 ± 2 20.6 ± 0.2 
  
0.25 148 ± 3 24.2 ± 0.4 
  
0.50 146 ± 5 28.8 ± 2.0 
  
1.00 159 ± 7 29.9 ± 1.8 
pH 7.4 L-CS-GLY40D7 0.10 236 ± 1 18.7 ± 1.9 
  
0.25 247 ± 5 23.4 ± 1.4 
  
0.50 243 ± 8 28.8 ± 3.2 
  
1.00 257 ± 14 24.4 ± 0.4 
 
L-CS-GLY40D34 0.10 139 ± 4 22.6 ± 0.9 
  
0.25 138 ± 5 27.7 ± 0.7 
  
0.50 144 ± 3 27.8 ± 1.0 
  
1.00 152 ± 9 30.4 ± 0.3 
Values shown correspond to the average of three independent measurements. 
 
The size results show that when the content of the hydrophobic segment was increased 
(D7 vs. D34), the particles become smaller and with almost the same average size for all 
concentrations tested. This phenomenon may be ascribed to the fact that larger substitution 
by DDA would cause more chains to aggregate, forming more compact hydrophobic cores. 
Furthermore, it may be noted that at pH 5 the particles formed by the sample L-CS-GLY40D7 at 
0.5 and 1.0 g/L have larger diameters due to electrostatic repulsion between the protonated 
CS chains. On the other hand, with the deprotonation of the polymer at pH 7.4, the particles 
tend to form more condensed structures. The pH seems to have little influence on the size of 
the particles formed by the sample L-CS-GLY40D34, since they are slightly higher at pH 5. 
 
ζ-potential values (+14.1 to +30.4 mV) suggest that CS chains are in direct contact with the 
external environment and are relatively stable. The positive charges on the surface of the 
nanoparticles can increase the biocompatibility of the system, allowing them to be used in 
biological applications such as drug and gene delivery.51 
The results shown here are similar to those previously reported30 for the self-assembling of 
amphiphilic CS quaternary ammonium derivatives. We have shown that both systems (with 
quaternary ammonium and glycidyl hydrophilic groups) have comparable behavior in 
aqueous solution and can form particles with a hydrophobic core. However, the derivatives 
produced by GLY series have lower average diameter, which indicates that they are more 
stable. We found that the size of nanoparticles, for both self-assembling systems, is 
influenced by various factors such as pH, concentration, hydrophilic/hydrophobic ratio, and 
nature of the hydrophilic group. Therefore, it can be concluded that both system may have 
specific self-assembling characteristics, which allows them to be used in different kinds of 
applications. 
 
Nanoparticles morphology was further investigated using TEM images (Figure 6). It was 
evident that the particles have spherical morphology, without significant aggregation among 
them, with sizes within the range determined by DLS. The differences in the diameters 
obtained by both techniques are due to the presence of water in the measurements by DLS, 






Representative TEM images of blank nanoparticles of (a) L-CS-GLY40D7 and (b) L-CS-
GLY40D34 at 0.5 mg/mL. 
 
DL and Release Studies 
 
Self-assembled nanoparticles can improve drug bioavailability and release profile in a 
sustained way. The hydrophobic compound QCT was loaded into the cores of the L-CS-GLY 
nanoparticles and the EE was determined using UV/vis spectroscopy. The EE was 73.2% for L-
CS-GLY40D7 and 77.7% for L-CS-GLY40D34. On the other hand, the DL decreased from 5.2% to 
4.3% for L-CS-GLY40D7 and L-CS-GLY40D34, respectively. As can be expected, the increase in the 
substitution by the DDA group promotes the increase of EE, due to the presence of more 
hydrophobic sites for interaction with QCT. The EE and DL for these samples are superior to 
those reported in similar studies.52-54 In spite of these observations, it is necessary to 
emphasize that the encapsulation process is complex and can be influenced by several 
factors, including CS molar mass, hydrophobic chain length, chemical drug structure, and 
drug–solvent interactions. 
 
The QCT release profiles at pH 5 and 7.4 are shown in Figure 7. As can be seen, there is a burst 
release effect during the first 8 h, probably due to weakly attached QCT on the surface of the 
nanoparticles. This step is followed by a constant release thereafter. For the L-CS-
GLY40D7 nanoparticle, after 96 h the drug release at pH 5 reached 82% and 60% at pH 7.4. A 
similar behavior was observed for the L-CS-GLY40D34 sample, with maximum release of 65% 
and 27% at pH 5 and 7.4, respectively. The electrostatic repulsion and formation of hydrogen 
bonds between water molecules and the protonated amino groups at pH 5 facilitates the 
diffusion and release of the QCT, while the absence of protonation at pH 7.4 reduces the 
amount of drug released. 
 
 Figure 7 
 In vitro release profile of QCT from (a) L-CS-GLY40D7 and (b) L-CS-GLY40D34 at pH 5.0 
 and 7.4 and 37 °C. 
 
The substitution by the C12 chain has also an important role over the release. While the L-CS-
GLY40D7 sample shows a lower EE, it has larger maximum release when compared to L-CS-
GLY40D34. This behavior may be ascribed to the interactions among the C12 chain and the 
hydrophobic QCT. The sample L-CS-GLY40D7 has fewer hydrophobic chains, thus QCT is weakly 
encapsulated in this sample. This explains why at pH 5 the sample L-CS-GLY40D7 has maximum 
release of 82% against 60% for the L-CS-GLY40D34 sample. 
 
In addition to the higher encapsulation capacity and pH sensitivity, the longer sustained 
release period is one of the main advantages of the carriers developed here. Other studies 
usually show nanocarriers promoting the release of drugs for 6,55 24,56 or 72 h,57 while our 
system allows sustained release for up to 96 h. Moreover, maintaining the drug's therapeutic 
levels for longer periods requires fewer applications during the treatment, reducing possible 
side effects of the drugs. 
 
The mathematical Korsmeyer–Peppas model was used to evaluate the release of QCT. This 
model has been widely used to characterize drug release mechanisms from spherical 
nanoparticles.13, 56, 58, 59 The fitting data (Table 4) revealed strong dependence on the pH, 
suggesting that there is a change in the outer layer of the nanoparticles as function of pH. 
These results indicate that there is influence of the medium on the structural characteristics 
of the nanoparticles. 
 
Table 4. Mathematical Parameters of the Release Data 
 
Sample pH K N Correlation value (R2) Type of diffusion 
L-CS-GLY40D7 5.0 20.7 ± 2.2 0.44 ± 0.01 0.9717 Anomalous 
 
7.4 6.3 ± 1.6 0.84 ± 0.17 0.9144 Anomalous 
L-CS-GLY40D34 5.0 25.4 ± 1.5 0.31 ± 0.04 0.9835 Fickian 
 
7.4 13.3 ± 1.5 0.22 ± 0.08 0.9027 Fickian 
 
The type of diffusion can be inferred from the n-coefficient obtained from the Korsmeyer–
Peppas model. It can be observed that the L-CS-GLY40D7 sample presented an anomalous 
diffusion (0.43 < n < 0.85) whereas the L-CS-GLY40D34 sample showed Fickian diffusion 
(n < 0.43). These results are in agreement with the release profiles observed in Figure 7, 
suggesting that the L-CS-GLY40D7 sample has larger release due to the anomalous diffusion 
mechanism. On the other hand, the L-CS-GLY40D34 sample has a lower release rate due to 
more controlled release from the nanoparticles. Therefore, according to the Korsmeyer–
Peppas model, the type of release depends on the degree of substitution of the hydrophobic 





The in vitro cytotoxicity of free QCT, CS, and its derivatives and QCT-loaded nanoparticles was 
evaluated by MTT assays. It can be seen in Figure 8(a) that the blank nanoparticles containing 
L-CS-GLY40D7 and L-CS-GLY40D34 showed MCF-7 cell viability higher than 70%. In fact, the cell 
viability for the derivatives was higher than that for non-modified CS (L-CS), suggesting that 
amphiphilic samples have improved biocompatibility, especially at the higher concentrations 
(25 and 50 µg/mL). The decrease in viability with the increase of the C12 chain evidences that 
the DDA group confers less biocompatibility, confirming that the hydrophobic content is 
directly related to the cytotoxic effect. On the other hand, the GLY might be responsible for 





 Figure 8 
 Cytotoxicity of nanoparticles against MCF-7 cells in 96-well plates determined using 
 the MTT assay. (a) Relative cell viability following treatment with L-CS and blank 
 nanoparticles at increasing concentrations. (b) Relative cell viability following 
 treatment with free QCT and QCT-loaded nanoparticles. Absolute concentrations refer 
 to concentration of QCT. For all experiments, cells were incubated for 24 h. Mean 
 values ± SD. (n = 3, ***P < 0.001). 
 
MTT assays were also used to evaluate the antitumor effect of free QCT and the QCT-loaded 
nanoparticles. Figure 8(b) shows that the reduction of the viability induced by the QCT-loaded 
nanoparticles was similar to that of the free drug after 24 h, regardless of the fact that only a 
fraction of the drug was released, as demonstrated by the in vitro release experiments. An 
immediate release of the total amount of QCT loaded into the nanoparticles would have led 
to a much higher cytotoxic response. The results, however, are in agreement with previous 
studies. Duo et al.60 have shown that QCT works by decreasing the proliferation and inducing 
apoptosis of MCF-7 cells over time. Recent studies have also showed the effectiveness of QCT 
against MCF-7 cells.61 
 
Therefore, QCT encapsulation may possibly decrease side effects upon systematic 
administration due to higher release in the acidic tumor tissue promoted by the amphiphilic 
carriers. Thus, the nanoparticles pH-sensitivity, sustained release, and the effectiveness of 
QCT suggest that the carriers studied here can be exploited in cancer therapy. 
 
Blood Compatibility Tests 
 
The blood compatibility of the new materials can be reliably assessed by the erythrocyte-
induced hemolysis test.62-64 It is important to ensure that no further interaction with 
erythrocytes occurs, otherwise it would negatively influence the circulation of the 
nanoparticles in the bloodstream. The hemolysis ratio for the L-CS-GLY40D7 and L-CS-
GLY40D34 samples were 3.2 ± 0.6 and 1.7 ± 0.2, respectively. These results are below the safety 
limit of 5% for pharmacological applications, suggesting good hemocompatibility. 
 
It has already been shown that CS has a haemolytic tendency.65, 66 This is due to the 
electrostatic interactions between the positive charges of the polymer and the negative 
charges of the cell structures. However, modification of the polymer backbone with GLY and 
DDA groups reduces the surface charges of the particles, improving its hemocompatibility. 
Similar results have already been reported.67 Biological molecules tend to adsorb on the 
surface of the particles upon intravenous administration, reducing its ability to damage the 
erythrocytes in the bloodstream.68 Moreover, the opsonization by serum or plasma proteins, 
known as opsonize, might also reduce the damage to the erythrocytes caused by the 




We have reported here a synthesis of novel amphiphilic derivatives of CS obtained by 
incorporating GLY and DDA to CS. Solubility experiments showed that insertion of the 
hydrophilic glycidyl group significantly increases the solubility of the polymer at pH above 6.2. 
Results showed that CS was easily modified in a successful and controlled reaction to promote 
self-assembling properties. Fluorescence experiments showed that copolymers self-assemble 
in aqueous solution at concentrations ranging from 0.003 to 0.047 g/L. 
 
The average size of the nanoparticles ranged from 130 to 300 nm and was dependent on pH, 
concentration, and hydrophilic/hydrophobic ratio, involving different types of associations 
among chains. ζ-potential values (+14.1 to +30.4 mV) showed that the particles were 
positively charged and stable in aqueous solution. TEM images confirmed the spherical 
morphology of the particles, without significant aggregation among them. 
 
The obtained particles can encapsulate QCT up to 78%. In vitro studies showed that the 
release occurs in two steps, being constant and slow after the initial 8 h, with significant 
influence of pH. The release mechanism, obtained from the mathematical Korsmeyer–Peppas 
model, showed dependence on the composition of the sample. Furthermore, the pH 
sensibility could be used to target specifically the tumour region, increasing the effectiveness 
of the drug and reducing its impact on health tissues. 
 
Cytotoxicity experiments confirmed that blank nanoparticles were non-cytotoxic. The results 
further revealed that QCT maintains its effectiveness against MCF-7 cells after encapsulation. 
The samples showed hemocompatibility, as demonstrated by hemolysis test. Therefore, the 
glycidyl-dodecyl amphiphilic CS derivatives might be used as pH-sensitive QCT delivery 
system. The carriers may help in reducing the side effects upon systematic administration of 
QCT. Thus, the systems developed in this study show biological and physicochemical 
parameters suitable for applications as a drug carrier. 
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